ImmunityBio
IBRX · NASDAQ
Bulios Fair Price
$11.23
33.1% upside
Current Price
$8.44
According to Bulios Fair Price, IBRX is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
ImmunityBio, Inc. (IBRX) is a biotechnology company specializing in the development of immunotherapeutic treatment therapies for various types of cancer and infectious diseases. The company is engaged in developing innovative approaches that activate patients' immune systems and help them fight diseases. ImmunityBio develops drugs that can stimulate immune response, enhance treatment efficacy, and increase the chances of successful outcomes. With the growing research in the field of immunotherapy and the need for new treatment approaches, ImmunityBio, Inc. has the potential for sustained growth. ImmunityBio, Inc. (IBRX) shares might be an interesting choice for investors seeking involvement in the biotechnology and immunotherapeutic treatment therapies industry.
Sector
Healthcare
Industry
Biotechnology
CEO
Richard Gerald Adcock
Employees
688
Headquarters
San Diego
Upcoming events
Earnings
Upcoming earnings report